No Data
No Data
Hims +6% Monday After FDA Said it Might Halt Hims Weight Loss Drug Sales Friday
Amgen's stock price has dropped, analysts warn that the speculation on weight loss drugs has already been digested by the market.
Amgen Inc.'s stocks fell on Monday after an analyst no longer holds a bullish view on this biotechnology giant, citing concerns that investor optimism about a candidate obesity drug has been reflected in the stock price, with more downside risks than upside opportunities. Truist analyst Srikripa Devarakonda downgraded the stock from buy for the past 11 months to hold. However, she raised the target price from $320 to $333, but the new target price is only 1.4% higher than last Friday's closing price. The stock traded down 1.1% in pre-market trading, following a rise last Friday
eli lilly and co (LLY.US) shifts investment focus to europe, investing 0.36 billion US dollars in the biotechnology sector in the united kingdom.
The pharmaceutical giant will also study the promotion of anti-obesity drugs in the united kingdom; the Labour government in the united kingdom is trying to attract more foreign investment.
Weight Loss Drugs Have One Big Issue; These Companies Want to Fix It
The good news for the obese population in the USA: FDA is considering allowing the combination version of eli lilly and co (LLY.US) weight loss drug.
(FDA) agreed on Friday to reconsider the decision made last month, which banned private drug compounders from selling their own compounded versions of eli lilly and co's weight loss and diabetes treatment drugs.
Top Gap Ups and Downs on Friday: TSLA, NVO, WFC and More
No Data
No Data